There are 50 million people living with chronic coronary artery disease in the U.S., Europe, and Japan. Of these, over 2 million suffer from acute coronary syndrome every year. In each case, the doctor and patient must decide whether to use more powerful therapy to prevent thrombosis – increasing the risk of bleeding – or less intensive therapy – reducing bleeding risk at the expense of more thrombotic events such as heart attack, stroke, and cardiovascular death.
Prolocor’s precision tool will guide treatment decisions, effectively matching the intensity of therapy with the risk of events. Founded by a team that deeply understands thrombosis and cardiovascular disease, Prolocor is building its strategy around platelet FcγRIIa and embarking on a journey to commercialize an innovative precision diagnostic test that quantifies FcγRIIa on the surface of platelets.
Company Details
- Employees
- 7
- Founded
- -
- Address
- Philadelphia, Pa 19146, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.prolocor.com/
- Keywords
- precision medicine, cardiovascular diagnostics, acute coronary syndrome, atherosclerosis, thrombosis, coronary artery disease, stroke, myocardial infarction, cardiovascular risk, cardiovascular disease.
- HQ
- Philadelphia, PA
Prolocor Questions
Prolocor's website is https://www.prolocor.com/
Prolocor's LinkedIn profile is https://www.linkedin.com/company/prolocor
Prolocor has
7 employees.
View email and phone details for 7
employees at Prolocor.
Prolocor's industry is
Biotechnology Research
Prolocor's top competitors are
Zbeats Inc.,
Rebel Medicine,
Inlighta Biosciences Llc,
Yaso Therapeutics Inc.,
Vero Biotech,
Plakous Therapeutics,
Sivec Biotechnologies Llc,
Terra Bioforge,
Inverdia,
Avanti Biosciences, Inc..
Prolocor's categories are Biotechnology Research
Prolocor's founding year is 2020
